Premium
High‐dose tirofiban with enoxaparin and inflammatory markers in high‐risk percutaneous intervention
Author(s) -
Walters D. L.,
Ray M. J.,
Wood P.,
Perrin E. J.,
Bett J. H. N.,
Aroney C. N.
Publication year - 2010
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2009.02237.x
Subject(s) - tirofiban , medicine , conventional pci , platelet activation , platelet , percutaneous coronary intervention , pharmacology , gastroenterology , cardiology , myocardial infarction
Eur J Clin Invest 2010; 40 (2): 139–147 Abstract Aim The study assessed the benefit of high bolus dose tirofiban (HD‐tirofiban) with enoxaparin compared with HD‐tirofiban with unfractionated heparin (UFH). The study examined markers of platelet activation, thrombin generation and inflammation. Materials and methods The study is a prospective single centre open‐label trial of patients with high‐risk acute coronary syndrome treated with percutaneous intervention (PCI) who were randomized to anticoagulation with UFH or enoxaparin with HD‐tirofiban (25 μg kg −1 bolus). This study measured a panel of platelet activation markers, inflammatory biomarkers and thrombus generation between the two groups. Result Sixty patients undergoing high‐risk PCI were enroled in the study. Platelet inhibition as assessed by whole blood aggregometry following HD‐tirofiban infusion was similar in both the UFH and enoxaparin groups. CD40 ligand expression on platelets was significantly reduced following PCI with HD‐tirofiban and either UFH or enoxaparin. Following PCI, there were significant reductions measured in other markers of platelet activation including PAC‐1, P selectin, factor V/Va, platelet‐monocyte aggregates and monocyte expression of Mac‐1 as determined by analysis of venous blood samples using flow cytometry. Prothrombin fragment 1+2, D‐dimer, von Willebrand factor and high sensitive C‐reactive protein levels were significantly less post PCI in the enoxaparin group compared with those patients receiving UFH. Conclusion The combination of HD tirofiban with enoxaparin resulted in an attenuated inflammatory response when compared with that of the combination of HD tirofiban with UFH.